Opioid-Induced Constipation Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major opioid-induced constipation markets reached a value of US$ 817.1 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1,166.9 Million by 2034, exhibiting a growth rate (CAGR) of 3.29% during 2024-2034.
The opioid-induced constipation market has been comprehensively analyzed in IMARC's new report titled "Opioid-Induced Constipation Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Opioid-induced constipation is a type of chronic constipation primarily caused by opioids, which activate enteric receptors and increase tonic non-propulsive contractions in the large and small intestines. This can slow down the movement of stool through the digestive system, leading to difficulty passing stool and infrequent bowel movements. The common symptoms associated with this ailment include abdominal tenderness, bloating, distention, or bulging in the abdomen, alternating episodes of constipation and diarrhea, dry and hard stools, nausea, vomiting, weight loss, difficulty defecating, fatigue, etc. The diagnosis is usually based on the evaluation of the patient's symptoms, along with a physical and rectal examination to visualize abdominal distension and stool impaction. The commonly utilized assessment tools for evaluating the severity of the condition are Bristol Stool Scale and Rome IV diagnostic criteria. In some cases, additional testing may be required to determine the underlying cause of the ailment. This may include colonoscopies to examine the digestive system as well as fecal occult blood testing to evaluate infections or other medical issues inducing constipation.
The escalating utilization of opioid medications for acute pain, such as after surgery or injury, and chronic pain, including that associated with cancer or certain other medical conditions, is primarily driving the opioid-induced constipation market. Moreover, the widespread adoption of effective drugs, such as mu-opioid receptor antagonists and chloride channel type-2 activators, which help enhance intestinal relaxation and stool movements to provide symptom relief, is also bolstering the market growth. In addition to this, the inflating application of several diagnostic tools, including Patient Assessment of Constipation Symptoms (PAC-SYM) and PAC-Quality of Life, (PAC-QOL) to measure abdominal and rectal symptoms, is acting as another significant growth-inducing factor. Furthermore, numerous key players are making extensive investments in R&D activities to introduce injectable opioid antagonists in order to treat advanced illnesses among patients. This, in turn, is also creating a positive outlook for the market. Additionally, the emerging popularity of the hybrid approach, which includes pharmacological therapy and lifestyle modifications, such as increasing dietary fiber, focusing on fluid intake, maintaining physical wellness, etc., for treating the ailment, is expected to drive the opioid-induced constipation market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the opioid-induced constipation market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for opioid-induced constipation and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the opioid-induced constipation market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the opioid-induced constipation market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the opioid-induced constipation market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current opioid-induced constipation marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the opioid-induced constipation market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the opioid-induced constipation market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the opioid-induced constipation market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of opioid-induced constipation across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of opioid-induced constipation by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of opioid-induced constipation by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with opioid-induced constipation across the seven major markets?
What is the size of the opioid-induced constipation patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of opioid-induced constipation?
What will be the growth rate of patients across the seven major markets?
Opioid-Induced Constipation: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for opioid-induced constipation drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the opioid-induced constipation market?
What are the key regulatory events related to the opioid-induced constipation market?
What is the structure of clinical trial landscape by status related to the opioid-induced constipation market?
What is the structure of clinical trial landscape by phase related to the opioid-induced constipation market?
What is the structure of clinical trial landscape by route of administration related to the opioid-induced constipation market?
The opioid-induced constipation market has been comprehensively analyzed in IMARC's new report titled "Opioid-Induced Constipation Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Opioid-induced constipation is a type of chronic constipation primarily caused by opioids, which activate enteric receptors and increase tonic non-propulsive contractions in the large and small intestines. This can slow down the movement of stool through the digestive system, leading to difficulty passing stool and infrequent bowel movements. The common symptoms associated with this ailment include abdominal tenderness, bloating, distention, or bulging in the abdomen, alternating episodes of constipation and diarrhea, dry and hard stools, nausea, vomiting, weight loss, difficulty defecating, fatigue, etc. The diagnosis is usually based on the evaluation of the patient's symptoms, along with a physical and rectal examination to visualize abdominal distension and stool impaction. The commonly utilized assessment tools for evaluating the severity of the condition are Bristol Stool Scale and Rome IV diagnostic criteria. In some cases, additional testing may be required to determine the underlying cause of the ailment. This may include colonoscopies to examine the digestive system as well as fecal occult blood testing to evaluate infections or other medical issues inducing constipation.
The escalating utilization of opioid medications for acute pain, such as after surgery or injury, and chronic pain, including that associated with cancer or certain other medical conditions, is primarily driving the opioid-induced constipation market. Moreover, the widespread adoption of effective drugs, such as mu-opioid receptor antagonists and chloride channel type-2 activators, which help enhance intestinal relaxation and stool movements to provide symptom relief, is also bolstering the market growth. In addition to this, the inflating application of several diagnostic tools, including Patient Assessment of Constipation Symptoms (PAC-SYM) and PAC-Quality of Life, (PAC-QOL) to measure abdominal and rectal symptoms, is acting as another significant growth-inducing factor. Furthermore, numerous key players are making extensive investments in R&D activities to introduce injectable opioid antagonists in order to treat advanced illnesses among patients. This, in turn, is also creating a positive outlook for the market. Additionally, the emerging popularity of the hybrid approach, which includes pharmacological therapy and lifestyle modifications, such as increasing dietary fiber, focusing on fluid intake, maintaining physical wellness, etc., for treating the ailment, is expected to drive the opioid-induced constipation market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the opioid-induced constipation market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for opioid-induced constipation and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the opioid-induced constipation market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the opioid-induced constipation market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the opioid-induced constipation market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current opioid-induced constipation marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the opioid-induced constipation market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the opioid-induced constipation market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the opioid-induced constipation market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of opioid-induced constipation across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of opioid-induced constipation by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of opioid-induced constipation by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with opioid-induced constipation across the seven major markets?
What is the size of the opioid-induced constipation patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of opioid-induced constipation?
What will be the growth rate of patients across the seven major markets?
Opioid-Induced Constipation: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for opioid-induced constipation drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the opioid-induced constipation market?
What are the key regulatory events related to the opioid-induced constipation market?
What is the structure of clinical trial landscape by status related to the opioid-induced constipation market?
What is the structure of clinical trial landscape by phase related to the opioid-induced constipation market?
What is the structure of clinical trial landscape by route of administration related to the opioid-induced constipation market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 OPIOID-INDUCED CONSTIPATION - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 OPIOID-INDUCED CONSTIPATION - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 OPIOID-INDUCED CONSTIPATION - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 OPIOID-INDUCED CONSTIPATION - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 OPIOID-INDUCED CONSTIPATION - UNMET NEEDS
10 OPIOID-INDUCED CONSTIPATION - KEY ENDPOINTS OF TREATMENT
11 OPIOID-INDUCED CONSTIPATION - MARKETED PRODUCTS
11.1 List of Opioid-Induced Constipation Marketed Drugs Across the Top 7 Markets
11.1.1 Amitiza (Lubiprostone) - Mallinckrodt
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Relistor (Methylnaltrexone bromide) - Bausch Health Companies/Progenics Pharmaceuticals
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Symproic (Naldemedine) - Shionogi
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Movantik (Naloxegol) - AstraZeneca/Nektar Therapeutics
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 OPIOID-INDUCED CONSTIPATION - PIPELINE DRUGS
12.1 List of Opioid-Induced Constipation Pipeline Drugs Across the Top 7 Markets
12.1.1 TD-1211 - Theravance
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Lactobacillus gasseri - BioGaia
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. OPIOID-INDUCED CONSTIPATION - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. OPIOID-INDUCED CONSTIPATION – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 OPIOID-INDUCED CONSTIPATION - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Opioid-Induced Constipation - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Opioid-Induced Constipation - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Opioid-Induced Constipation - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Opioid-Induced Constipation - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Opioid-Induced Constipation - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Opioid-Induced Constipation - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Opioid-Induced Constipation - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Opioid-Induced Constipation - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Opioid-Induced Constipation - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Opioid-Induced Constipation - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Opioid-Induced Constipation - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Opioid-Induced Constipation - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Opioid-Induced Constipation - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Opioid-Induced Constipation - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Opioid-Induced Constipation - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Opioid-Induced Constipation - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Opioid-Induced Constipation - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Opioid-Induced Constipation - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Opioid-Induced Constipation - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Opioid-Induced Constipation - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Opioid-Induced Constipation - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Opioid-Induced Constipation - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Opioid-Induced Constipation - Access and Reimbursement Overview
16 OPIOID-INDUCED CONSTIPATION - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 OPIOID-INDUCED CONSTIPATION MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 OPIOID-INDUCED CONSTIPATION MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 OPIOID-INDUCED CONSTIPATION - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 OPIOID-INDUCED CONSTIPATION - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 OPIOID-INDUCED CONSTIPATION - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 OPIOID-INDUCED CONSTIPATION - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 OPIOID-INDUCED CONSTIPATION - UNMET NEEDS
10 OPIOID-INDUCED CONSTIPATION - KEY ENDPOINTS OF TREATMENT
11 OPIOID-INDUCED CONSTIPATION - MARKETED PRODUCTS
11.1 List of Opioid-Induced Constipation Marketed Drugs Across the Top 7 Markets
11.1.1 Amitiza (Lubiprostone) - Mallinckrodt
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Relistor (Methylnaltrexone bromide) - Bausch Health Companies/Progenics Pharmaceuticals
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Symproic (Naldemedine) - Shionogi
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Movantik (Naloxegol) - AstraZeneca/Nektar Therapeutics
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 OPIOID-INDUCED CONSTIPATION - PIPELINE DRUGS
12.1 List of Opioid-Induced Constipation Pipeline Drugs Across the Top 7 Markets
12.1.1 TD-1211 - Theravance
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Lactobacillus gasseri - BioGaia
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. OPIOID-INDUCED CONSTIPATION - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. OPIOID-INDUCED CONSTIPATION – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 OPIOID-INDUCED CONSTIPATION - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Opioid-Induced Constipation - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Opioid-Induced Constipation - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Opioid-Induced Constipation - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Opioid-Induced Constipation - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Opioid-Induced Constipation - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Opioid-Induced Constipation - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Opioid-Induced Constipation - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Opioid-Induced Constipation - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Opioid-Induced Constipation - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Opioid-Induced Constipation - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Opioid-Induced Constipation - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Opioid-Induced Constipation - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Opioid-Induced Constipation - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Opioid-Induced Constipation - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Opioid-Induced Constipation - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Opioid-Induced Constipation - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Opioid-Induced Constipation - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Opioid-Induced Constipation - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Opioid-Induced Constipation - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Opioid-Induced Constipation - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Opioid-Induced Constipation - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Opioid-Induced Constipation - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Opioid-Induced Constipation - Access and Reimbursement Overview
16 OPIOID-INDUCED CONSTIPATION - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 OPIOID-INDUCED CONSTIPATION MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 OPIOID-INDUCED CONSTIPATION MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
